# US 5,700,486 A · Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,700,486 A - Document ID: US5700486A - Status: Granted - Kind: A - Application number: 08/641,039 - Filed: 1996-04-30 - Granted: 1997-12-23 - Earliest claimed: 1990-11-22 - Assignees: Vectorpharma International S.p.A. - Inventors: Tiziana Canal; Mara Lucia Lovrecich; Fabio Carli - Web page: https://patentgrep.com/patent/US5700486A ## CPC - A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)} - A61K 9/1617: {Organic compounds, e.g. phospholipids, fats} - A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)} - Y10T 428/2991: Coated - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract Pharmaceutical compositions in the form of particles comprising a biodegradable polymer and/or a polysaccharide jellifying and/or bioadhesive polymer, an amphiphilic polymer, an agent modifying the interface properties of the particles and a pharmacologically active substance. Said compositions exhibit improved biocompatibility features and allow a controlled release of the active substance. ## Claims ### Claim 1 Process for the preparation of pharmaceutical compositions in the form of particles suitable for the controlled release of a pharmaceutically active substance comprising a biodegradable polymer, an amphiphilic polymer, an agent modifying the interface properties at a concentration between 0.1 and 99.9% and a pharmaceutically active substance at a concentration between 0.01 and 99.9% wherein: (a) the biodegradable polymer and amphiphilic polymer and the agent modifying the interface properties are co-solubilized in the presence or absence of solvents to form a mixture; (b) the pharmaceutically active substance is dissolved or dispersed in the mixture; (c) the obtained mixture is brought in the from of particles having diameter comprised between 0.1 and 150 .mu.m by means of emulsifying or extruding or spray-drying or spray-congealing techniques; (d) said particles are optionally washed and dried according to classical methods. ### Claim 2 (depends on 1) Process according to claim 1, wherein the technique of emulsifying, the outer phase of the emulsion comprises such an amount of amphiphilic polymer and/or active agent to minimize the partition. ### Claim 3 (depends on 1) Process according to claim 1, wherein in the technique of extruding, the mixture consisting of the polymeric compounds, the agent modifying the interface properties, the pharmaceutically active substance and the amphiphilic polymer is extruded by means of a heat-extrusor and the extruded material is granulated or micronized. ### Claim 4 (depends on 1) Process according to claim 1, wherein in the technique of spray-drying, the mixture consisting of the polymeric compounds, amphiphilic polymer, agent modifying the interface properties, pharmaceutically active substance and solvent or solvent mixture is sprayed at temperature higher than the solvent evaporation point thus obtaining the composition in the form of particles. ### Claim 5 (depends on 1) Process according to claim 1, wherein in the technique of spray-congealing, the mixture consisting of the polymeric compounds, agent modifying the interface properties, pharmaceutically active substance and solvent is sprayed at temperature lower than the congealing temperature of the employed solvent and the resulting powder is lyophilized. ### Claim 6 (depends on 1) Process according to claim 1, wherein said biodegradable polymer is selected from the group consisting of polylactic acid, polyglycolic acid and co-polymers thereof, polyhydroxybutyric acid, polycaprolacton, polyorthoesters, polyanhydrides, chitins, chitosans, hyaluronic acid, collagen and co-polymers thereof. ### Claim 7 (depends on 1) Process according to claim 1, wherein the polysaccharide polymer is selected from the group consisting of scleroglucane, xanthan, chitins and chitosans, cellulose and derivatives thereof and alginates. ### Claim 8 (depends on 1) Process according to claim 1, wherein said amphiphilic polymer is selected from the group consisting of polyethyleneglycols, polyvinylpyrrolidones and polyvinylalcohols. ### Claim 9 (depends on 1) Process according to claim 1, wherein said agents modifying the interface properties are surface active agents selected from the group consisting of sorbitan esters, polysorbates, lecithins, stearic acid and stearates. ### Claim 10 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is selected from the group consisting of central nervous system active medicaments, cardiovasculars, hypotensives, diuretics, antiphlogistics, analgesics, antipyretics, antiasthma, bronchodilatators, antitussives, mucolytics, antibiotics, chemotherapeutics antivirus, hormones, antineoplastics, immunosupressors, immunostimulants, proteins, polypeptides, vaccines. ### Claim 11 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is calcitonin. ### Claim 12 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is selected from the group of LH-RH analogues. ### Claim 13 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is (Des-Gly, D-Trp.sup.6, Pro.sup.9 -ethylamide) LH-RH analogue. ### Claim 14 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is somatostatin. ### Claim 15 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is somatotropin. ### Claim 16 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substances are broxaterol and hydrochloride thereof. ### Claim 17 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is nicergoline. ### Claim 18 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is megestrol acetate. ### Claim 19 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is levonorgestrel. ### Claim 20 (depends on 1) Process according to claim 1, wherein said pharmaceutically active substance is adriamycin.